Where does it <scp>FIT</scp>? The roles of fecal testing and colonoscopy in colorectal cancer screening

Hillyer, Grace Clarke; Neugut, Alfred I.

doi:10.1002/cncr.29459

Cited by 3 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Successful models of mass public health CRC prevention with qFIT screening have been implemented in the UK, Canada, and selectively in the US [27]. In integrated health systems, such as Kaiser Permanente and the federally funded Veterans Health Administration (VA) where quality and cost efficiency are king, qFIT is the most commonly‐used CRC screening method.…”

Section: Symptomatic Patientsmentioning

confidence: 99%

Is the quantitative faecal immunochemical test (qFIT) ready for prime time in the US?

Keller

2022

Colorectal Disease

View full text Add to dashboard Cite

Despite increased awareness, advances in treatment and innovation in surgical approaches, colorectal cancer (CRC) is still a worldwide public health issue [1]. The cause is multifactorial, but physical inactivity, gut bacteria, unhealthy diet, being overweight or obese, smoking and alcohol use all play a role. Small decreases in overall incidence rates are overshadowed by the exponential rise in early onset CRC. In 2021, there will be an estimated 149,500 new cases and 52,980 deaths from CRC in the United States (US) alone [2]. While the majority of CRCs are diagnosed in adults aged 50 and older, 12% are now diagnosed in individuals younger than age 50; the equivalent of 49 new cases daily. Colorectal cancer is the second most common cancer and the third leading cause of cancer-related death in those less than 50 [3].

show abstract

Section: Symptomatic Patientsmentioning

confidence: 99%

Is the quantitative faecal immunochemical test (qFIT) ready for prime time in the US?

Keller

2022

Colorectal Disease

View full text Add to dashboard Cite

show abstract

“…[20][21][22][23][24] The information about reliable test performance of the NBCSP screening test is especially welcome as measures such as false-negative rate for cancer often receive little attention in population-based screening programs. 25 It should also be noted that one of the key indicators of the program's success is its cost-effectiveness. As an example of the cost and clinical differential in screening, the NBCSP is highly effective at detecting advanced adenomas (precancerous polyps), 26 the diagnosis and removal of which costs on average less than $2000 in the Australian health system.…”

Section: Broader Contextmentioning

confidence: 99%

Compelling new data on the effectiveness of Australia's National Bowel Cancer Screening Program: A model for best practice?

John

Grogan

2016

Asia-Pac J Clncl Oncology

View full text Add to dashboard Cite

“…6 In order to reach the unscreened portion of the screening-eligible population many large healthcare organizations have adopted organized population-based screening programs using high sensitivity fecal occult blood testing (e.g. the fecal immunochemical test [FIT]), 7 making FIT the second most commonly used CRC screening modality in the U.S. Organized FIT screening is particularly well-suited to CRC screening for individuals that may be resistant to the use of colonoscopy, who are not good candidates for this procedure due to comorbidities, or who are unable to access endoscopic services.…”

Section: Introductionmentioning

confidence: 99%

Primary care visit use after positive fecal immunochemical test for colorectal cancer screening

Hillyer

Jensen

Zhao

et al. 2017

Cancer

Self Cite

View full text Add to dashboard Cite

Background For some patients, positive cancer screening test results can be a stressful experience which can affect future screening compliance and increase the utilization of healthcare services unrelated to medically-indicated follow-up. Methods Among 483,216 individuals, aged 50–75 years, who completed a fecal immunochemical test to screen for colorectal cancer at a large integrated health care setting between 2007 and 2011, we evaluated whether a positive test was associated with a net change in outpatient primary care visit use in the year following screening. We used multivariable regression models to evaluate the relationship between test result group and net changes in primary care visits following fecal immunochemical test. Results In the year following the fecal immunochemical test, utilization increased by 0.60 clinic visits for true positives. The absolute change in visits was largest (3.00) among test positive patients diagnosed with colorectal cancer but significant small increases were also found for polypectomy/no neoplasia (0.36) and normal exam/no polypectomy (0.17). Groups that demonstrated an increase in net visit use compared to the true negative group included true positives (OR 1.60, 95% CI 1.54–1.66), and positive groups with colorectal cancer diagnosis (OR 7.19, 95%CI 6.12–8.44), polypectomy/no neoplasia (OR 1.37, 95%CI 1.27–1.48) and normal exam/no polypectomy groups (OR 1.24, 95%CI 1.18–1.30). Conclusion Given the large size of outreach programs, these small changes can cumulatively generate thousands of excess visits and have substantial impacts on total health care utilization and thus should be included in colorectal cancer screening cost models and their causes investigated further.

show abstract

Where does it FIT? The roles of fecal testing and colonoscopy in colorectal cancer screening

Cited by 3 publications

References 25 publications

Is the quantitative faecal immunochemical test (qFIT) ready for prime time in the US?

Is the quantitative faecal immunochemical test (qFIT) ready for prime time in the US?

Compelling new data on the effectiveness of Australia's National Bowel Cancer Screening Program: A model for best practice?

Primary care visit use after positive fecal immunochemical test for colorectal cancer screening

Contact Info

Product

Resources

About